Paragon Therapeutics

What Paragon Therapeutics does

Paragon Therapeutics is a private biotechnology venture creator founded in 2020 and based in Waltham, Massachusetts. The company operates a platform model in which an in-house team of approximately 30–50 scientists discovers and engineers complex antibody-based biologics, then spins out independent partner companies to advance those assets through clinical development and commercialization. To date, Paragon has generated six spin-out companies (Apogee Therapeutics in 2022, Spyre Therapeutics in 2023, Oruka Therapeutics, Jade Biosciences, Crescent Biopharma, and Korsana Biosciences) and approximately 12 therapeutic candidates currently in clinical development across immunology, inflammatory bowel disease, chronic skin disease, autoimmune conditions, oncology, and neurodegenerative disease.

The platform rests on three proprietary technology layers: a broad antibody engineering and protein engineering toolkit used for biologics discovery and optimization, a proprietary CMC model that supports rapid and reliable progression from ideation to the clinic (lead programs have entered the clinic in under two years from ideation), and the THETA blood-brain-barrier penetration platform developed for Korsana that enables next-generation shuttled antibodies to cross into the central nervous system. High-throughput screening systems and optimization techniques underpin the discovery workflow. The pipeline spans approximately 28 named programs across partnered companies and undisclosed internal discovery programs (including multiple IND-enabling assets).

Paragon's business model is asset-centric rather than product-centric: revenue and upside are generated through licensing agreements and equity stakes in spin-off companies rather than direct product sales. Each spin-out is capitalized by external investors — for example, Korsana was funded with $25M from Fairmount and Venrock (seed) plus a $150M Series A co-led by Wellington Management and TCGX with participation from Sanofi Ventures and JPM Life Sciences Private Capital, and Oruka completed a public offering of approximately $700 million in 2026. Paragon itself serves partner biotechnology companies as its primary customer segment, addressing the industry-wide need for rapid, best-in-class complex biologics discovery for major unmet medical needs; the company does not disclose public product pricing.

Name

Paragon Therapeutics

Legal name

Paragon Therapeutics

Website

https://paragontherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Paragon Therapeutics is a private biotechnology venture creator that discovers and engineers complex antibody-based biologics, then spins out independent partner companies to advance them through clinical development for major unmet medical needs.

Ownership category

akta.pro rank

Product category

Biologics Discovery and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industries

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Biologics discovery
• Antibody engineering
• Therapeutic licensing
• Venture creator biotech
• Protein engineering platform

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Spin-off Companies: Paragon generates therapeutic candidates and forms spin-off companies around assets discovered by and licensed from Paragon. Revenue is generated through licensing agreements and equity stakes in spun-out companies. To date, the company has generated multiple therapeutic candidates, 12 of which are being advanced in clinical development by partner companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Paragon Therapeutics is a biotechnology venture creator that uses proprietary antibody engineering, protein engineering, and high-throughput screening technologies to discover and optimize novel biologic therapeutic candidates. It then advances these candidates by forming or licensing them to dedicated spin-off partner companies that carry the assets into clinical development, generating licensing revenue and equity participation across a portfolio of more than 12 clinical-stage programs.

Product overview

Paragon Therapeutics is a biotechnology company that operates as a technology and product platform focused on antibody discovery and biologics development. The company applies cutting-edge protein engineering technologies to identify novel therapeutic concepts with best-in-class potential and rapidly advance them into clinical development. To date, Paragon has generated multiple therapeutic candidates, with 12 programs currently in clinical development by partner companies including Apogee Therapeutics (immunological/inflammatory disorders), Spyre Therapeutics (IBD), Oruka Therapeutics (chronic skin diseases), Jade Biosciences (autoimmune conditions), and Crescent Biopharma (oncology). The company utilizes high-throughput screening systems, optimization techniques, and an internal CMC model to execute efficient program timelines from ideation through clinical development. Paragon operates multiple partnered programs across discovery, IND-enabling, and clinical stages.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 6 biotech companies successfully spun out with multiple clinical-stage programs
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Apogee TherapeuticscoreStrategic or Co-development Partner · 25 June 2026Apogee Therapeutics is the first company formed around assets discovered by and licensed from Paragon. Established in 2022, Apogee is advancing a pipeline of potentially best-in-class product candidates targeting immunological and inflammatory disorders including Atopic Dermatitis, asthma, and COPD. In June 2026, AbbVie announced acquisition of Apogee for approximately $10.9 billion.
• Spyre TherapeuticscoreStrategic or Co-development PartnerSpyre Therapeutics is the second company formed around assets discovered by and licensed from Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates for inflammatory bowel disease (IBD) and other immune-mediated diseases, combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations.
• Oruka TherapeuticscoreStrategic or Co-development PartnerOruka Therapeutics is the third company formed around assets discovered by and licensed from Paragon. Established in 2024, Oruka is advancing potentially best-in-class biologics for chronic skin diseases including plaque psoriasis. Oruka has amended its IL-23 License Agreement with Paragon to expand development rights. The company raised approximately $700 million in a public offering in 2026.
• Jade BiosciencescoreStrategic or Co-development PartnerJade Biosciences is the fourth company formed around assets discovered by and licensed from Paragon. Jade is developing best-in-class therapies for autoimmune diseases, with lead candidate JADE101 targeting APRIL for IgA nephropathy treatment. Jade announced first patient dosed in Phase 2 trial for JADE101 in May 2026.
• Crescent BiopharmacoreStrategic or Co-development PartnerCrescent Biopharma is the fifth company formed around assets discovered by and licensed from Paragon. Crescent is advancing a pipeline of precision-engineered molecules for solid tumors, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates.
• Korsana BiosciencescoreStrategic or Co-development PartnerKorsana Biosciences is the sixth company emerged from Paragon Therapeutics, developing next-generation biologics for neurodegenerative diseases using the proprietary THETA blood-brain barrier penetration platform developed in partnership with Paragon. Korsana emerged with $175 million in total funding to advance KRSA-028 for Alzheimer's disease.
• GalectominorStrategic or Co-development PartnerGalecto has an antibody discovery and option agreement with Paragon Therapeutics. As part of this agreement, Galecto issued a warrant to Paramora Holding LLC in December 2025 for the purchase of up to 628,302 shares at $23.01 per share. Galecto subsequently acquired Damora Therapeutics in November 2025.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genmab: Genmab is a specialized antibody therapeutics company that develops and licenses antibody programs to large pharma partners (notably Janssen and AbbVie). Paragon's model of licensing antibody assets to partner companies mirrors Genmab's partnership-driven commercialization strategy.
• PureTech Health: PureTech is a clinical-stage biotherapeutics company that founds and develops wholly-owned subsidiaries around therapeutic platforms. Its hub-and-spoke biotech creation model is structurally similar to Paragon's spin-out strategy, though historically focused on a broader range of modalities.
• AbCellera Biologics: AbCellera operates a leading antibody discovery platform that discovers candidates and partners with biotech/pharma for development — including notable responses during the COVID-19 pandemic. Paragon similarly builds on proprietary antibody discovery technologies and partners program development externally.
• BridgeBio Pharma: BridgeBio operates a multi-asset biotech platform that creates and advances multiple drug programs across rare diseases, retaining control until key value inflection points. Like Paragon, it serves as a parent creation engine for therapeutic candidates, though focused on small molecules and gene therapies.
• Roivant Sciences: Roivant is the prototypical biotech venture creator that builds subsidiary 'Vants' around therapeutic assets, retains equity, and spins them out with focused development. Paragon replicates this model with antibody-focused biologics rather than small molecules, making it the closest structural analog.

Emerging players

• Inhibrx: Inhibrx was a clinical-stage biotech developing antibody-based therapeutics for oncology and orphan diseases, acquired by Sanofi in 2024 in a deal valuing its lead asset at over $2 billion. Comparable scale and asset model — antibody-engineering focused biotech with similar partnership/buyout outcomes.
• Compass Therapeutics: Compass is a clinical-stage antibody-focused biotech developing novel therapeutics for autoimmune diseases and oncology with multiple partnered programs. Comparable overlap with Paragon's portfolio of antibody programs targeting immunology and oncology through external partners.
• Werewolf Therapeutics: Werewolf is a clinical-stage biotech focused on engineered antibody-based therapeutics for oncology, with proprietary INDUKINE and PREDATOR platform technologies. Comparable to Paragon's partnered oncology candidate with Crescent Biopharma (PD-1xVEGF bispecific, ADCs).
• Adagene: Adagene is a clinical-stage biotech using proprietary antibody engineering platforms (POWERbody, SAFEbody) to develop differentiated antibody therapeutics, primarily in oncology. Both companies build on differentiated antibody-engineering platforms and pursue partnership-based development for their discovered assets.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is the gold-standard antibody discovery and engineering company, built on the VelociSuite technologies and validated by multiple FDA-approved antibodies (e.g., Eylea, Dupixent). Paragon's antibody engineering platform targets the same biologics discovery category with a venture-creation commercialization twist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/paragon-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paragon Therapeutics